Metabolic Restoration Strategies for Insulin Resistance

Unlock the secrets of metabolic restoration for better health management and improved quality of life from insulin resistance.

Abstract

In this educational post, I guide you through a clear, evidence-based exploration of how insulin resistance drives a broad spectrum of chronic diseases—and why correcting this upstream dysfunction can transform outcomes across endocrinology, hepatology, cardiometabolic health, oncology, and neurology. I discuss the latest data on retatrutide, a triple receptor agonist (GLP-1/GIP/Glucagon), spotlighting clinical findings on glycemic control, insulin independence, non-alcoholic steatohepatitis (NASH) resolution, weight loss, and potential reductions in cancer incidence. I integrate these advances with a holistic model of care delivered at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas, where our multidisciplinary team blends chiropractic care, functional and integrative medicine, personal injury rehabilitation, and medical oversight.

This post details how I, Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, clinical lead of integrative chiropractic care, collaborate with Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933), our Medical Director and Collaborative Physician with over 40 years of internal medicine experience. Together, we apply modern, evidence-based protocols to address root-cause physiology, including hyperinsulinemia, adipose tissue dysfunction, inflammation, and autonomic imbalance. We cover the underlying mechanisms, clinical applications, safety considerations, and ethical dimensions of metabolic therapeutics—always emphasizing patient-centered, multidisciplinary care.

Throughout, I share clinical observations from our practice and my published insights on WellnessDoctorRx and in my professional updates to show how integrative chiropractic care fits into a structured, medically supervised pathway that aligns lifestyle, movement, neuromusculoskeletal balance, and precision therapeutics to restore health and function.

Keywords we will explore include: insulin resistance, hyperinsulinemia, GLP-1 receptor agonists, GIP, glucagon signaling, retatrutide, metabolic syndrome, NAFLD/NASH, adipokines, gut-brain axis, autonomic regulation, mechanotransduction, musculoskeletal rehabilitation, and functional medicine.

Understanding the Upstream Problem: Insulin Resistance as a Systemic Driver

• Insulin resistance is a persistent, upstream metabolic dysfunction that underlies a large fraction of chronic diseases. The consequence is persistent hyperinsulinemia—chronically elevated insulin—which can precede a diagnosis of type 2 diabetes by 10–20 years.
• This hyperinsulinemia affects not only glucose homeostasis but also influences growth factor signaling, lipid metabolism, hepatic fat accumulation, vascular function, and inflammation.
• In clinical practice, I find that patients often present with pain, fatigue, weight gain, brain fog, and sleep disturbances—yet their root issue traces back to metabolic signaling misaligned by diet, lifestyle, chronic stress, toxins, and genetic susceptibilities.

The multi-decade arc of hyperinsulinemia

• The progression from insulin resistance to type 2 diabetes typically takes years. Hyperinsulinemia maintains normoglycemia for a prolonged period, masking the problem while driving downstream pathophysiology such as dyslipidemia, hypertension, fatty liver, and pro-growth signaling in tumors.
• Integrative chiropractic care supports autonomic regulation, mechanical load distribution, and movement efficiency—key modulators of metabolic stress. When combined with medical oversight and functional therapies, we can interrupt this trajectory.

Why hyperinsulinemia matters beyond glucose

• Elevated insulin interacts with IGF-1 pathways, which modulate cellular growth and proliferation. This is relevant to tissues like breast, colon, and endometrium that express IGF receptors, contributing to oncologic risk when metabolic dysfunction persists.
• Elevated insulin also drives hepatic de novo lipogenesis, leading to non-alcoholic fatty liver disease (NAFLD) and progression to NASH, fibrosis, and even cirrhosis in susceptible individuals.
• The cardiovascular system suffers from endothelial dysfunction, elevated sympathetic tone, and pro-inflammatory signaling—bringing hypertension, atherosclerosis, and heart failure risk into the picture.

Clinical takeaway

• Treating downstream diseases without addressing the upstream engine—insulin resistance and hyperinsulinemia—delays, but does not prevent, disease progression. Our model targets the root, stabilizes physiology, and then supports the system through lifestyle, movement, and targeted pharmacology when appropriate.

Introducing Our Multidisciplinary Model: Medical Direction and Chiropractic Integration

• At Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas, we deliver integrated care where an MD provides medical direction alongside a chiropractor—an increasingly common model in integrative and injury care.
• I serve as the chiropractic and functional medicine lead, bringing advanced training in family practice nursing and integrative therapeutics. In contrast, Dr. Maria Guadalupe Cardenas, MD—Board Certified in Internal Medicine (NPI #1164426749, Texas MD License #J2933)—serves as our Medical Director and Collaborative Physician.

Roles in our integrative team

• Cardenas oversees medical evaluation, risk assessment, and pharmacologic management to ensure safety and adherence to best practices. Her 40+ years of internal medicine experience anchor our program in rigorous clinical standards.
• I apply integrative chiropractic care, clinical nutrition, neuromusculoskeletal assessment, and functional medicine frameworks to modulate autonomic balance, reduce pain, improve movement patterns, and support metabolic flexibility.
• Our rehabilitation team addresses post-injury recovery and chronic pain, emphasizing biomechanical correction, endurance building, and tissue resilience.
• Together, we align metabolic correction with structural and neurological optimization—a synergy that accelerates patient outcomes.

How this integration helps patients

• Patients benefit from hands-on care that reduces pain and improves function, while also receiving medical evaluation for metabolic syndrome, NAFLD, hypertension, diabetes risk, and inflammatory burden.
• This dual-lens approach ensures we don’t miss emergent medical issues while capitalizing on the restorative potential of movement, nutrition, sleep optimization, stress reduction, and targeted therapeutics.

The New Therapeutic Landscape: GLP-1/GIP/Glucagon Triple Agonists

• Recent advances in incretin-based therapy have transformed metabolic care. Beyond GLP-1 receptor agonists, triple agonists like retatrutide engage GLP-1, GIP, and glucagon receptors to orchestrate multi-system metabolic improvements.
• Early clinical signals suggest robust glycemic control, significant weight loss, liver fat reduction, and improved cardiovascular risk markers.

Mechanistic overview

• GLP-1: Enhances glucose-dependent insulin secretion, suppresses glucagon when glucose is high, slows gastric emptying, and induces satiety via central pathways.
• GIP: Potentiates glucose-dependent insulin secretion, may support adipose tissue remodeling, and, in combination with GLP-1, appears to improve weight loss and metabolic flexibility.
• Glucagon: Elevates energy expenditure via hepatic and brown adipose mechanisms, promotes lipolysis and fatty acid oxidation, and in a triple-agonist stack, paradoxically synergizes with GLP-1/GIP to reduce hepatic steatosis and improve weight loss.

Why triple agonism matters

• Metabolic syndrome is not a single-lane disorder. It involves disrupted energy intake, storage, expenditure, and signaling. A triple agonist addresses multiple levers simultaneously:

• • Improves insulin sensitivity and glycemic control.
  • Reduces appetite and increases satiety.
  • Increases energy expenditure.
  • Mobilizes and oxidizes hepatic and visceral fat stores.
  • May improve fibrosis via decreased lipotoxicity and inflammation.

Retatrutide: Evidence Signals and Clinical Context

• Clinical trials of retatrutide have reported marked improvements in glycemic control and weight reduction. Some analyses suggest substantial reductions in the need for exogenous insulin among patients with type 2 diabetes under specific trial conditions.
• Studies in NASH and NAFLD populations indicate improved liver histology and reductions in liver fat, with some data pointing to fibrosis regression in a substantial subset.

Glycemic control and insulin sparing

• Early reports have highlighted that a notable proportion of type 2 diabetes patients achieved significant reductions in exogenous insulin requirements when treated with retatrutide under medical supervision, with glucose-dependent mechanisms reducing hypoglycemia risk relative to basal-bolus intensification.
• The practical implication in clinic: under MD oversight, carefully structured deprescribing protocols can accompany retatrutide initiation for selected patients, with continuous glucose monitoring (CGM) and staged dose titration to ensure safety.

NASH resolution signals

• Triple agonist mechanisms align with hepatic lipid reduction and inflammation control. Clinical studies have reported high rates of NASH resolution and reductions in fibrosis scores, suggesting this class may be uniquely positioned for metabolic liver disease.
• For patients with elevated ALT/AST, steatosis on imaging, or FibroScan evidence of fibrosis, we pair retatrutide consideration (when appropriate) with staged nutritional therapy, resistance training, weight-bearing movement, and hepatic support strategies.

Oncology and metabolic risk

• Obesity and insulin resistance are associated with increased risk for several cancers. Incretin therapy has been associated in observational analyses with reduced incidence of some obesity-related cancers; ongoing research continues to clarify causality and magnitude of effect.
• Any potential oncologic benefits from metabolic therapies are secondary to comprehensive risk-reduction strategies: weight management, nutrition quality, inflammation control, sleep, stress reduction, and avoiding tobacco and excess alcohol.

Important caveats

• Triple agonists are potent. Gastrointestinal side effects, gallbladder risk, pancreatitis concerns, and thyroid tumor warnings in some GLP-1 class labels necessitate careful patient selection and monitoring.
• Our medical oversight ensures we navigate contraindications and interactions, including concurrent insulin or sulfonylureas, pregnancy status, medullary thyroid carcinoma risk, and pancreatitis history.

How Integrative Chiropractic Care Fits In: Mechanobiology Meets Metabolism

• A vibrant metabolism depends on movement, autonomic balance, and neuromuscular coherence. Integrative chiropractic care provides a unique lens to modulate these domains:

• • Spinal and joint adjustments influence proprioceptive input and central integration, which can shift autonomic tone toward parasympathetic balance and improve digestion, insulin sensitivity, and vascular function.
  • Soft tissue work, therapeutic exercise, and postural rehabilitation improve glucose uptake by skeletal muscle, the body’s largest glucose sink, enhancing mitochondrial function and glucose transporter (GLUT4) translocation.
  • Pain reduction encourages activity, breaking cycles of inactivity, weight gain, and cardiometabolic decline.

Physiological mechanisms we leverage

• Mechanotransduction: Tissues sense and respond to mechanical forces. Proper loading improves cartilage health, bone density, tendinous resilience, and muscle insulin sensitivity.
• Autonomic modulation: Adjustments and breathing retraining can reduce sympathetic overdrive—a state linked to hypertension, impaired insulin signaling, and sleep disruption.
• Myofascial dynamics: Fascia influences circulation, lymphatic return, and interoception. Restoring gliding and elasticity improves perfusion and clears metabolic waste.

Clinical observations in our practice

• Over the years, I have observed that patients who receive integrative chiropractic care alongside medical and nutritional interventions achieve:

• • Better adherence due to reduced pain and improved function.
  • Faster gains in activity tolerance and VO2 reserve.
  • More sustainable weight loss and metabolic improvements due to enhanced movement capacity.

• These observations are echoed in my professional writings on WellnessDoctorRx and professional updates, underscoring the practical synergy of structural care with metabolic therapy.

Building an Integrative Protocol: Stepwise, Evidence-Informed, Patient-Centered

• Our model begins with comprehensive assessment and proceeds in staged interventions that respect physiology and patient readiness.

Step 1: Comprehensive assessment

• Medical intake and labs under Dr. Cardenas:

• • Fasting glucose, insulin, HbA1c, lipid panel, hs-CRP, LFTs.
  • CGM initiation when indicated.
  • Imaging for hepatic steatosis/fibrosis if clinically warranted.
  • Blood pressure and autonomic markers.

• Chiropractic and functional assessment under my guidance:

• • Posture, gait, mobility, and stability screening.
  • Pain mapping and functional limitation profiling.
  • Review of sleep, stress, and nutrition intake.

• Risk stratification:

• • Evaluate for contraindications to incretin therapy.
  • Identify red flags for cardiac, hepatic, or oncologic risk requiring referral or co-management.

Step 2: Foundational interventions

• Nutritional strategy:

• • Emphasize whole foods, higher protein proportion, fiber diversity, and controlled energy intake.
  • Align meal timing with circadian rhythms to optimize insulin dynamics.

• Movement plan:

• • Resistance training 2–3 days per week; daily walking; mobility work.
  • Graded exposure for deconditioned patients, progressing load and complexity.

• Sleep and stress:

• • Set sleep-wake consistency; incorporate breathwork and vagal maneuvers.
  • Evaluate for sleep-disordered breathing when suggested by symptoms.

Step 3: Integrative chiropractic care

• Targeted spinal and extremity adjustments, myofascial release, instrument-assisted techniques.
• Neuromotor retraining: scapular control, lumbopelvic stability, foot core function.
• Pain desensitization and graded movement exposure to restore autonomy and confidence.

Step 4: Pharmacologic augmentation when indicated

• Under Dr. Cardenas’ oversight, consider retatrutide or other incretin therapy for patients meeting criteria after foundational care initiation.
• Titrate dosing carefully, manage GI side effects, and adjust concurrent medications as needed to avoid hypoglycemia or hypotension.
• Continue CGM and periodic lab monitoring; adjust plan based on data.

Step 5: Reinforcement and maintenance

• Behavioral coaching and relapse prevention.
• Periodic chiropractic recalibration visits to maintain alignment, mobility, and autonomic balance.
• Data-driven personalization: iterate nutrition and exercise based on biomarkers and functional goals.

Transform Your Body!- Video

Addressing the Broader Health Landscape: Obesity, Diabetes, and Cancer Risk

• Obesity prevalence remains high among American adults, and the number of individuals with prediabetes and diabetes continues to rise. Obesity-related cancers make up a significant fraction of total cancer incidence.
• Metabolic dysfunction is a unifying theme across these domains; improving insulin sensitivity and reducing visceral adiposity can mitigate risk.

Why these statistics matter in clinic

• Behind every number is a person with pain, family responsibilities, and aspirations. Our job is to translate statistics into individualized, achievable plans that restore health and autonomy.

Retatrutide and access considerations

• High-cost medications limit access and may inadvertently maintain downstream demand for chronic disease treatments. Ethical care weighs patient benefit against systemic implications.
• In our clinic, we prioritize foundational therapies accessible to all, while integrating advanced therapeutics for those who qualify and can benefit safely.

Safety, Ethics, and Clinical Governance

• Integrative care demands rigorous safety protocols and ethical practice:

• • Clear informed consent and education about benefits, risks, and alternatives.
  • Monitoring for adverse effects, particularly GI symptoms, gallbladder issues, pancreatic symptoms, and thyroid-related warnings with incretin-based agents.
  • Nuanced deprescribing strategies for insulin and sulfonylureas to avoid hypoglycemia.
  • Coordination across specialties when liver disease, cardiovascular disease, or oncology risk requires additional expertise.

• Dr. Cardenas provides medical oversight, ensuring that protocols align with current evidence and regulatory frameworks, while I ensure neuromusculoskeletal and lifestyle components are executed with fidelity.

Practical Case Patterns and Observations

• Case pattern 1: Middle-aged patient with metabolic syndrome, back pain, and sleep disruption.

• • Outcome: With chiropractic care, movement retraining, nutritional alignment, and incretin therapy when indicated, we often see improved pain, better sleep, weight loss, and normalized glycemic markers.

• Case pattern 2: NAFLD with elevated ALT/AST and reduced activity tolerance.

• • Outcome: Progressive resistance training, spinal and hip mobility restoration, nutrition-focused liver fat reduction, and consideration of triple agonist therapy under MD care lead to improved liver enzymes and energy.

• Case pattern 3: Post-injury patient with weight gain and insulin resistance.

• • Outcome: Integrative rehab reduces pain, restores function, and enables weight management; metabolic therapy is added when needed to accelerate visceral fat reduction and insulin sensitivity.

Detailed Physiology: Why Each Technique Matters

• Spinal adjustments and autonomic balance:

• • By optimizing afferent input from the spine and related joints, adjustments can modulate dorsal horn processing and brainstem autonomic centers, reducing sympathetic dominance. This shift supports improved vascular compliance, digestion, and insulin signaling.

• Resistance training and insulin sensitivity:

• • Mechanical loading increases GLUT4 translocation and mitochondrial biogenesis in muscle, improving glucose disposal and resting metabolic rate.

• Nutritional timing and glycemic control:

• • Aligning meals with circadian rhythms improves insulin action and lipid handling. Reducing evening calorie load can improve overnight glycemia and morning insulin sensitivity.

• Incretin therapy rationale:

• • GLP-1 and GIP enhance glucose-dependent insulin release and reduce appetite; glucagon agonism increases energy expenditure and lipid oxidation. Together, these mechanisms address energy intake and expenditure, reduce ectopic fat, and improve liver health.

Our Team-Based Workflow

• Intake to assessment: Coordinated scheduling for medical and chiropractic evaluations ensures seamless care.
• Case conference: I meet with Dr. Cardenas to review labs, imaging, and progress. We co-create a plan that balances structural, metabolic, and behavioral strategies.
• Patient education: We prioritize simple, clear explanations so patients understand the why behind each step.
• Follow-up cadence: Initially frequent to stabilize care, then tapered as patients gain confidence and control.

Patient Education: Translating Science into Action

• We teach patients how to read their CGM trends, understand the impact of meals and exercise, and interpret theirbody’ss signals.
• We emphasize that no medication can replace movement, sleep, and nutrition—but advanced therapies can create an opportunity for sustainable habit change.

The Future of Metabolic Care in an Integrative Clinic

• Triple agonists may redefine standards, but the foundation remains: restore metabolic flexibility and reduce mechanical stress.
• Integrative chiropractic care will remain a key modality for neuromusculoskeletal harmony and autonomic balance.
• With medical direction from experienced internists like Dr. Cardenas, we ensure safety, efficacy, and alignment with evolving guidelines.

Final Thoughts: Compassion, Clarity, and Commitment

• Metabolic dysfunction is complex, but solvable. Our clinic’s multidisciplinary model ensures that patients receive comprehensive, evidence-based care anchored in both medicine and movement.
• I care deeply about translating cutting-edge science into real-world outcomes, and I am committed to guiding patients with clarity, compassion, and integrity.

References

• American Diabetes Association. Standards of Medical Care in Diabetes—2024 (American Diabetes Association, 2024).
• Centers for Disease Control and Prevention. Adult Obesity Facts (CDC, 2023).
• American Cancer Society. Obesity and Cancer (American Cancer Society, 2023).
• Glucagon-like peptide-1 receptor agonists in obesity and type 2 diabetes: mechanisms and clinical outcomes (Lancet Diabetes & Endocrinology, 2024).
• Incretin-based triple agonists for obesity and NASH: emerging evidence and mechanistic insights (Lancet Gastroenterology & Hepatology, 2024).
• GLP-1 receptor agonists and colorectal cancer risk reduction: observational analyses (JAMA Oncology, 2023).
• Nonalcoholic fatty liver disease: pathophysiology and treatment strategies (Gastroenterology, 2023).
• Mechanotransduction in musculoskeletal and metabolic health (Nature Reviews Molecular Cell Biology, 2023).
• Autonomic regulation and metabolic disease: clinical implications (Endocrine Reviews, 2024).
• Lifestyle intervention and resistance training for metabolic syndrome: outcomes and mechanisms (JAMA Internal Medicine, 2023).

Note: References are provided for educational purposes. Patients should consult their healthcare providers for personalized medical advice.

SEO tags: integrative chiropractic care, insulin resistance, hyperinsulinemia, retatrutide, GLP-1 GIP glucagon triple agonist, metabolic syndrome, NAFLD, NASH, functional medicine, autonomic balance, mechanotransduction, El Paso chiropractic clinic, Dr Alex Jimenez, Dr Maria Guadalupe Cardenas, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, obesity care, diabetes care, oncology risk reduction